<div id="readability-page-1"><p>Strs Ohio trimmed its holdings in shares of  ResMed Inc. (NYSE:RMD - Free Report) by 89.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,497 shares of the medical equipment provider's stock after selling 30,494 shares during the period. Strs Ohio's holdings in ResMed were worth $842,000 at the end of the most recent quarter.</p><ul><li>HCA Healthcare Rallies: Weight-loss drugs really a big threat?</li></ul><p>Several other hedge funds have also bought and sold shares of RMD. Jones Financial Companies Lllp increased its holdings in shares of  ResMed by 52.6% during the 1st quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider's stock valued at $645,000 after purchasing an additional 994 shares in the last quarter.  Arrowstreet Capital Limited Partnership acquired a new position in shares of  ResMed in the 2nd quarter valued at $389,000.  Brown Advisory Inc. lifted its stake in shares of  ResMed by 17.8% in the 2nd quarter. Brown Advisory Inc. now owns 1,586 shares of the medical equipment provider's stock valued at $409,000 after purchasing an additional 240 shares during the period.  Cresset Asset Management LLC acquired a new position in shares of  ResMed in the 2nd quarter valued at $206,000.  Finally, Alliancebernstein L.P. lifted its stake in shares of  ResMed by 24.2% in the 2nd quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider's stock valued at $73,808,000 after purchasing an additional 55,790 shares during the period. Hedge funds and other institutional investors own  54.98% of the company's stock. </p><h2>Insiders Place Their Bets</h2><p>In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total transaction of $450,000.00. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Michael J. Farrell sold 4,991 shares of the company's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $273.78, for a total transaction of $1,366,435.98. Following the transaction, the chief executive officer owned 466,223 shares of the company's stock, valued at $127,642,532.94. This represents a 1.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 18,973 shares of company stock valued at $4,715,237 over the last 90 days. 0.65% of the stock is currently owned by company insiders. </p><h2>Analysts Set New Price Targets</h2><p>Several equities analysts recently issued reports on the stock. Citigroup decreased their target price on shares of ResMed from $345.00 to $340.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, April 9th. KeyCorp decreased their target price on shares of ResMed from $302.00 to $290.00 and set an &#34;overweight&#34; rating for the company in a research note on Monday, April 27th. Evercore  set a $255.00 target price on shares of ResMed and gave the company an &#34;outperform&#34; rating in a research note on Monday, April 13th. JPMorgan Chase &amp; Co. assumed coverage on shares of ResMed in a research note on Wednesday, April 15th. They issued an &#34;overweight&#34; rating for the company. Finally, Wall Street Zen cut shares of ResMed from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, March 14th. One research analyst  has rated the stock with a Strong Buy rating, nine have assigned  a Buy rating and five have issued  a Hold rating to the stock. According to MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $286.18.</p><p><b>Check Out Our Latest Analysis on ResMed</b></p><h2>ResMed Stock Performance</h2><p>NYSE:RMD opened at $206.83 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The company has a fifty day moving average of $230.41 and a two-hundred day moving average of $245.04. The stock has a market capitalization of $30.13 billion, a PE ratio of 19.94, a P/E/G ratio of 1.34 and a beta of 0.84. ResMed Inc. has a fifty-two week low of $198.64 and a fifty-two week high of $293.81. </p><p>ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping analysts' consensus estimates of $2.79 by $0.07. The company had revenue of $1.43 billion during the quarter, compared to analysts' expectations of $1.42 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The firm's revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.37 earnings per share.  As a group, research analysts forecast that  ResMed Inc. will post 11.13 earnings per share for the current fiscal year. </p><h2>ResMed Dividend Announcement</h2><p>The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Thursday, May 14th will be given a dividend of $0.60 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a yield of 1.2%. ResMed's dividend payout ratio  is currently 23.14%. </p><h2>ResMed Company Profile</h2> (Free Report)<p>ResMed <span>NYSE: RMD<span></span></span> is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.  </p><p>ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.</p><h2>Read More</h2><ul><li>Five stocks we like better than ResMed</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ResMed Right Now?</h2><p>Before you consider ResMed, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.</p><p>While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Strs Ohio reduced its holdings in ResMed Inc. (NYSE:RMD) by 89.7% in Q4, owning 3,497 shares after selling 30,494 shares. Other hedge funds have also adjusted their positions, with Jones Financial increasing its stake by 52.6%. Insiders sold shares totaling $4.7 million in the last 90 days. Analysts have set new price targets, with Citigroup lowering its target to $340 and KeyCorp to $290. ResMed's stock opened at $206.83, with a market cap of $30.13 billion and a PE ratio of 19.94. The company reported earnings of $2.86 per share, exceeding estimates.</p>

Market Beat

Resmed

SPDR S&P Health

iShares US Medical Devices

SPDR S&P Health Equip

HCA Healthcare

AllianceBernstein

Citigroup

KeyCorp

Evercore

JPMorgan Chase

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

CITIGROUP INC 6.250 NON CUM SER II PFD WI

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

ResMed Inc. $RMD Shares Sold by Strs Ohio